(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
FDA official discusses potential link between COVID-19 vaccines and pediatric deaths- Monetary Security: Building Serious areas of strength for an Establishment
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Tech for Learning: Online Courses and Instructive Apparatuses
- Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- Thermo Fisher wins contracts as pharma shifts production to US, CEO says
- Scientists captured female sperm whales on video working together during a birth to protect the calf
- Underestimated Metropolitan Experience Urban communities On the planet
